Our findings have uncovered a new mechanism through which different Aβ aggregates evoke abnormal tau accumulation in neurons, and suggest that targeting the DAPK1/Pin1 pathway could be a useful strategy for the intervention in Aβ aggregation-induced neuropathological changes throughout the progression of AD. Here, MAPT is linked to Alzheimer disease.